Published

A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of Psychopharmacology
Date: 2026-05-01
Source: Crossref
DOI: 10.1177/02698811261424214
PubMed: 41825921

Authors

Moreno Francisco A.Allen Katja E.Wiegand Christopher B.Dunne Rajan Prickett James I.Bayze Brian Allen John J. B.

Watch author

Derived topics and classifications

psilocybin OCD Receptor Pharmacology Clinical Trial Safety Adverse Events Clinical Trial

Citation graph

29 referenced DOIs found in stored source metadata. 4 indexed papers cite this DOI.

Open citation network

10.1176/appi.books.9780890425596 10.1177/02698811231224217 10.1016/j.neuroimage.2020.116980 10.1002/cpt.2487 10.1038/s41598-023-39812-0 10.1124/pr.118.017160 10.3389/fnhum.2014.00020 10.3389/fpsyt.2025.1726818 10.1038/s41591-022-01744-z 10.1523/jneurosci.1659-20.2020 10.1007/7854_2021_279 10.1177/02698811241237870

Indexed papers citing this DOI

Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions2026-07-02 Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review2026-07-01 A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder2026-05-01 Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins2026-04-21

Related papers

Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01